Muscle Loss and GLP-1 Weight-Loss Drugs: What the Latest Clinical Trials Really Show (2026 Update)
Medically reviewed by Dr. Michael Koehler, MD | Affinity Whole Health
The explosion of GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) has transformed obesity and type 2 diabetes treatment. These medications deliver impressive weight loss—often 15–25% of body weight—along with major cardiometabolic benefits. But as millions use them, a key question has emerged: How much muscle are people losing, and does it matter?
Headlines sometimes paint a dire picture of sarcopenia (age-related muscle loss) risk. The reality from clinical trials is more nuanced—and increasingly optimistic with new data and strategies. Here's a clear, evidence-based breakdown using the latest randomized controlled trials, real-world analyses, and imaging substudies as of mid-2026.
Why the Concern Exists
Weight loss from any method (diet, bariatric surgery, or GLP-1s) typically involves some loss of lean body mass alongside fat. Lean mass includes skeletal muscle, organs, bone, water, and glycogen. Rapid weight loss can accelerate this if protein intake drops or physical activity decreases.
For older adults or those with low baseline muscle (sarcopenic obesity), excessive loss could theoretically impair strength, metabolism, and mobility. GLP-1s suppress appetite dramatically, which can reduce overall calorie and protein intake if not managed intentionally.
What the Landmark Trials Showed
STEP-1 Trial (semaglutide 2.4 mg weekly): Participants lost about 15% of body weight. DXA scans showed lean mass decreased by roughly 13%, accounting for ~40–45% of total weight lost. However, the proportion of lean mass relative to total body weight actually increased slightly, indicating overall improved body composition (more fat lost relatively).
SURMOUNT-1 Trial (tirzepatide up to 15 mg weekly): Greater average weight loss (~21%). Lean mass loss was about 11%, representing ~25% of total weight lost—suggesting relatively favorable preservation of lean tissue in the context of greater overall weight reduction.
These DXA-based numbers fueled discussion, but they have important limitations we'll address below.
2025–2026 Data: A More Complete Picture Emerges
Newer studies provide critical context on actual muscle quality, function, and real-world outcomes:
Real-World Evidence: Tirzepatide vs Semaglutide
Real-world observational studies confirm that both semaglutide and tirzepatide produce substantial weight loss in routine clinical practice, often exceeding that seen in earlier trials for certain populations. However, dedicated analyses of differential effects on lean body mass (LBM) in real-world settings remain limited. Emerging data suggest that body composition changes may vary between agents, reinforcing the value of personalized monitoring and the need for additional peer-reviewed research using standardized body composition assessment methods. Observational findings should be interpreted cautiously due to potential confounding factors such as differences in patient populations, dosing patterns, diet, and physical activity levels.
Muscle Quality Often Improves
The SURPASS-3 MRI substudy (tirzepatide in type 2 diabetes) showed reductions in myosteatosis—fat infiltration within muscle tissue. This is a marker of poorer muscle quality and metabolic dysfunction. Reducing it is a positive signal for muscle health and function, even if total lean mass declines modestly.
Functional Outcomes Are Often Preserved or Improved
Recent prospective and observational studies indicate that while absolute lean mass may decrease with GLP-1 therapy, muscle strength and physical function frequently improve due to reduced body weight (less joint stress), better glycemic control, reduced inflammation, and increased mobility. Many patients report feeling stronger and more capable after significant weight loss on GLP-1s—especially when paired with activity. Real-world data also shows preservation of lean mass and muscle function in many patients treated with tirzepatide.
Important Context and Caveats
Measurement Matters: DXA "lean mass" includes water, glycogen, and organs—not just skeletal muscle. Caloric deficits cause rapid shifts in these, inflating apparent "muscle loss" early on. MRI and strength testing provide better pictures of true skeletal muscle.
Proportion vs. Absolute: Even when 25–40% of weight lost is "lean," the majority is still fat. Overall body composition (fat-to-lean ratio) typically improves.
Comparison to Alternatives: Similar or greater lean mass loss occurs with very-low-calorie diets or bariatric surgery. GLP-1s are not uniquely "muscle-wasting."
Context of the Data – Primarily Obese Populations: The majority of rigorous clinical trial data on GLP-1 medications and body composition comes from studies in obese individuals (typically BMI ≥30 kg/m² or ≥27 with weight-related conditions). These patients often start with higher body fat percentages and, in many cases, lower relative muscle mass or more sedentary habits.
For individuals who are overweight but not obese, or who are already physically active with good baseline muscle mass and consistent nutrition, muscle mass preservation during GLP-1 therapy is typically much better. Many active patients experience minimal or no clinically significant muscle loss when they prioritize resistance training and adequate protein intake from the start. The concerning headlines are often driven by data from less active, more obese cohorts. Active, non-obese patients generally fare far better.
Not All GLP-1s Are Equal: Dual agonists like tirzepatide show some advantages in trial body comp data but mixed real-world signals. Newer agents and strategies are closing gaps rapidly.
Practical Strategies to Protect Muscle on GLP-1 Therapy
Based on trial protocols and expert consensus:
Resistance Training: 2–3 sessions per week targeting major muscle groups. This is the single most effective intervention. Ongoing trials are formally testing combined protocols with semaglutide and tirzepatide.
Protein Intake: Aim for 1.2–1.6+ g per kg of ideal or adjusted body weight daily (often 25–40g per meal). Prioritize leucine-rich sources (whey, eggs, meat, dairy, or supplements). Spread throughout the day.
Caloric Deficit Management: Avoid excessively rapid loss and aim for less than 2 pounds of body weight to lose per week; work with your provider on sustainable dosing and nutrition.
Monitoring: Track strength (e.g., grip strength, ability to do push-ups or chair stands), energy, and function. Consider advanced body comp analysis with our complimentary InBody scanners at baseline and 6–12 months if concerned.
Lifestyle Synergy: Prioritize sleep, stress management, and staying active (walking + strength work).
Advanced Options for Muscle Preservation: TRT and Sermorelin
When clinically appropriate after comprehensive lab testing and medical evaluation, hormone optimization can play a powerful supporting role in protecting muscle during weight loss:
Testosterone Replacement Therapy (TRT)
Men with clinically low or suboptimal testosterone levels often experience accelerated muscle loss during calorie restriction and GLP-1 therapy. When medically indicated, TRT helps preserve and build lean muscle mass, improves energy and motivation for exercise, supports better body composition, and can enhance overall results. It requires proper diagnosis, ongoing monitoring, and is not suitable for everyone.
Sermorelin Therapy
Sermorelin is a growth hormone-releasing hormone (GHRH) peptide that stimulates your own pituitary gland to produce more natural growth hormone. Age-related or other declines in GH contribute to muscle loss, increased fat storage, slower recovery, and reduced vitality. For patients who qualify, Sermorelin can help preserve muscle mass, improve sleep quality and recovery, support fat metabolism, and enhance overall body composition during GLP-1 treatment. It has a favorable safety profile when properly monitored and is used in both men and women.
These therapies are not for everyone. They are prescribed only when there is a clear clinical need after thorough evaluation. They form part of our personalized, comprehensive approach to "quality weight loss"—maximizing fat loss while actively safeguarding muscle, metabolic health, and long-term vitality.
The Bottom Line
GLP-1 medications deliver profound health benefits that extend far beyond the scale. While they do cause some lean mass reduction—as does virtually any effective weight-loss method—the latest clinical trial data (including real-world analyses and MRI substudies) shows this is manageable, often not disproportionate to fat loss, and frequently accompanied by improvements in muscle quality and physical function.
Importantly, much of the data highlighting greater muscle loss comes from obese, often less active populations. Active individuals and those who are overweight but not severely obese generally experience significantly better muscle preservation—especially when resistance training and protein intake are prioritized from day one.
For most people, the cardiometabolic gains, reduced inflammation, and improved quality of life far outweigh the manageable muscle effects—especially when resistance training, adequate protein, and (when clinically appropriate) hormone optimization with TRT or Sermorelin are part of the plan.
The future looks even brighter with ongoing research into strategies that support optimal body composition during weight loss.
If you're considering or already using a GLP-1 medication, discuss body composition goals with your AWH provider. Personalized strategies including strength training, nutrition optimization, and when indicated, advanced therapies like TRT or Sermorelin can help you achieve the highest-quality weight loss possible.
Ready to Protect Your Muscle While Losing Fat?
Our team at Affinity Whole Health specializes in comprehensive, personalized weight-loss programs that combine GLP-1 therapy with nutrition, resistance training protocols, body composition tracking, and—when clinically appropriate—hormone optimization with TRT or Sermorelin. We focus on quality weight loss that protects your metabolism and long-term health, with a dedicated Patient Care Coordinator there for you every step of the way.
Schedule your free consultation today to discuss your goals and create a plan tailored to you.
This is for informational purposes only and not medical advice. Always consult your physician before starting, stopping, or changing any medication or exercise program. Individual responses vary. TRT and Sermorelin are prescription therapies available only to patients who meet clinical criteria after proper evaluation.